Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

4109 - Survival analysis of KRAS, NRAS, BRAF, PIK3CA wild type (wt) metastatic colorectal cancer (mCRC) patients (pts) treated with FOLFIRI plus cetuximab in the CAPRI- GOIM trial


09 Sep 2017


Poster display session


Cytotoxic Therapy;  Translational Research;  Colon and Rectal Cancer


Erika Martinelli


Annals of Oncology (2017) 28 (suppl_5): v158-v208. 10.1093/annonc/mdx393


E. Martinelli1, C. Cardone2, T. Troiani2, N. Normanno3, S. Pisconti4, R. Bordonaro5, A. Nappi6, F. Giuliani7, M. Biglietto8, C. Barone9, A.M. Rachiglio3, V. Montesarchio10, S. Cinieri11, D. Rizzi12, A. Febbraro13, T.P. Latiano14, G. Modoni4, G. Colucci3, E. Maiello15, F. Ciardiello2

Author affiliations

  • 1 Oncologia Medica, Dipartimento Di Internistica Clinica E Sperimentale “f. Magrassi”,, Università degli Studi della Campania Luigi Vanvitelli, 80131 - Napoli/IT
  • 2 Oncologia Medica, Dipartimento Di Internistica Clinica E Sperimentale “f. Magrassi”,, Università degli Studi della Campania Luigi Vanvitelli, 80121 - Napoli/IT
  • 3 Cell Biology Unit, Istituto Nazionale Tumori – I.R.C.C.S - Fondazione Pascale, 80131 - Napoli/IT
  • 4 Oncologia Medica
, Stabilimento SS. Annunziata, Taranto/IT
  • 5 Medical Oncology Unit A, Azienda Ospedaliera ARNAS Garibaldi, 95100 - Catania/IT
  • 6 Medical Oncology, Istituto Nazionale Tumori – I.R.C.C.S - Fondazione Pascale, 80131 - Napoli/IT
  • 7 Medical Oncology, Istituto Tumori Giovanni Paolo II, 70126 - Bari/IT
  • 8 Medical Oncology, Azienda Ospedaliera "A. Cardarelli", Napoli/IT
  • 9 Department Of Medical Oncology, Università Cattolica del Sacro Cuore, 20123 - Roma/IT
  • 10 Medical Oncology Unit, AORN dei Colli Monaldi Hospital, Napoli/IT
  • 11 Medical Oncology Unit A, Perrino Hospital, 72100 - Brindisi/IT
  • 12 Trial Office, GOIM, Bari/IT
  • 13 Medical Oncology Unit A, Ospedale "Sacro Cuore di Gesù" Fatebenefratelli, 82100 - Benevento/IT
  • 14 Oncologia Ed Ematologia, Casa sollievo della sofferenza, San Giovanni Rotondo/IT
  • 15 Oncologia, IRCCS Casa Sollievo della Sofferenza, 71013 - San Giovanni Rotondo/IT


Abstract 4109


The CAPRI-GOIM trial consisted of two parts: FOLFIRI plus cetuximab in first line followed by cetuximab plus FOLFOX as second line treatment for molecularly selected mCRC pts. The primary endpoint was progression-free survival (PFS). Secondary endpoints included overall survival (OS), response rate and safety. This is an updated analysis providing the mature results for OS in KRAS, NRAS, BRAF, PIK3CA wt pts.


In the CAPRI-GOIM trial 340 mCRC pts with KRAS exon 2 wt tumors were treated in first line with FOLFIRI plus cetuximab until disease progression or unacceptable toxicity. After first line therapy progression, pts (157), who achieved a clinical response with first line treatment, were randomized to FOLFOX plus cetuximab (Arm A) or to FOLFOX (Arm B). Archival tissue samples from primary tumours were centrally assessed by next generation sequencing (NGS) with the Ion AmpliSeq Colon and Lung cancer panel. Here we report mature survival data at median follow-up of 69 months (m) (cut off date: April 30, 2017) for 98 out of the 124 RAS wt patients with NGS analysis, that were representative of the 340 intention to treat patient population.


Median OS for these 98 pts was 34.0 m (95% CI 30.2–37.8) with PFS of 11.7 m (95% CI 10.3–13.1). Eighty six out of 98 pts had tumors that were KRAS, NRAS, BRAF, PIK3CA wt. In this cohort, OS was 35.8 m (95% CI 29.9–41.9) with PFS of 12.3 m (95% CI 10.7–14.0). PFS and OS were also evaluated according to tumour location (see Table for results).Table:


CohortMedian OS (months)Median PFS (months)
RAS wt (n = 98)33.4 (31.7- 34.9)35.8 (29.9- 41.7)9.9 (7.9- 12.0)12.3 (11.0- 13.6)
KRAS, NRAS, BRAF, PIK3CA wt (n = 86)34.0 (22.1- 46.0)35.8 (29.5- 42.3)9.9 (5.3- 14.6)12.3 (10.7- 14.0)


Long-term follow-up analysis of pts enrolled in the CAPRI-GOIM trial showed a median OS of approximately 36 m in KRAS, NRAS, BRAF and PIK3CA wt pts. A better prognostic outcome in terms of OS and PFS was observed in left-sided as compared to right-sided tumors.

Clinical trial identification

EudraCT number 2009-014041-81

Legal entity responsible for the study

Gruppo Oncologico dell'Italia Meridionale (GOIM)


Cetuximab was provided by Merck Serono. Other funding: AIRC


E. Martinelli: Advisory Board: Merck serono, Amgen. F. Ciardiello: Advisory Board: Merck Serono, Roche, Amgen, Pfizer, Bayer, Lilly. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.